Metrics as of 10/13/2026, 06:30 PM (Berlin time), refresh in progress.
Relay Therapeutics Stock
Relay Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sanjiv K. Patel
- Employees
- 202
- Market cap
- $3.9 B
- IPO
- 16/07/2020
Relay Therapeutics, Inc. is a healthcare company based in Cambridge, US, operating within the biotechnology industry. The company's mission focuses on revolutionizing the drug discovery process by enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. Its pipeline…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Relay Therapeutics stock: price history
1D
-2.0%
1W
-6.0%
1M
-6.7%
6M
+19.4%
YTD
+108.2%
1Y
+180.9%
2Y
+159.0%
5Y
-37.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~10% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Relay Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Relay Therapeutics is a precision medicine company that aims to revolutionize drug discovery through computational modeling. The company focuses on designing small molecules for the treatment of cancer and genetic disorders. Relay is currently in the clinical development phase with several drug candidates including RLY-4008, RLY-2608, and RLY-1971. Strategic partnerships, such as with Genentech, Inc., support the development and future commercialization of therapeutics.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Relay Therapeutics
Analyst assessment of Relay Therapeutics
PRICE TARGET LOW
US$18.00
CONSENSUS
US$26.25
MEDIAN
US$27.50
PRICE TARGET HIGH
US$31.00
1
STRONG BUY
14
BUY
0
HOLD
0
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 20/08/2026
Relay Therapeutics stock metrics
P/E
-11.21
P/B
4.01
EV/EBITDA
-13.27
RETURN ON EQUITY
-9.4%
NET MARGIN
-23,916.3%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.3%
FLOAT SHARES
171,502,282
AVG. DAILY VOLUME (30D)
3,264,676
Insider transactions (SEC)
Catinazzo Thomas
Patel Sanjiv
Catinazzo Thomas
Bergstrom Donald A
Patel Sanjiv
Institutional holders
Comparable stocks
Frequently asked questions about Relay Therapeutics stock
What does Relay Therapeutics do?
Relay Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sanjiv K. Patel, the company employs around 202 people.
The IPO was on 16/07/2020; the stock trades on NASDAQ under the ticker RLAY.
What do analysts say about Relay Therapeutics stock?
15 analysts rate the stock, the consensus is Buy (as of 20/08/2026).
The average price target is US$26.25, ranging from US$18.00 to US$31.00, with a median of US$27.50.
This is an external assessment, not a statement by Market Jury.
When does Relay Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Relay Therapeutics pay a dividend?
No, Relay Therapeutics currently does not pay a dividend.
Which stocks are comparable to Relay Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Relay Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Relay Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.